• Provision of consent

• Patient has a confirmed diagnosis of sickle cell disease

• At least 2 episodes of vaso-occlusive crises in the past 12 months

• Hemoglobin ≥ 5.5 and ≤ 10.5 g/dL (≥ 55 and ≤ 105 g/L) during screening

• Patients taking hydroxyurea, must demonstrate a stable dose for at least 90 days prior to start of study treatment

• Patients on crizanlizumab or L-glutamine treatment at the time of consent must be on a stable dose for ≥ 12 months and must be ≥ 80% compliant with the planned regimen at the time of consent and meet the VOC eligibility criteria

• Female patients of childbearing potential must use highly effective methods of contraception, male patients are willing to use barrier methods of contraception